当前位置: 首页 > 期刊 > 《人人健康·医学导刊》 > 2008年第3期
编号:12062465
27例多西他赛联合顺铂治疗晚期非小细胞肺癌的疗效观察
http://www.100md.com 2008年3月1日 《人人健康·医学导刊》 2008年第3期
27例多西他赛联合顺铂治疗晚期非小细胞肺癌的疗效观察

     【摘要】目的:探讨多西他赛联合顺铂(DDP)在治疗晚期非小细胞肺癌中的疗效及毒副反应。方法:27例晚期非小细胞肺癌患者,给予多西他赛与顺铂联合治疗,21天为一个治疗周期,至少2周期评价疗效。结果:全组27例中,完全缓解(CR)2例,部分缓解(PR)9例,无变化(NC)8 例,进展(PD)8例,总有效率(OR)为40.74%。主要不良反应为血液学毒性,中性粒细胞下降、血小板下降和血红蛋白下降的发生率分别为70.37%,33.33%和51.85%。结论:多西他赛联合顺铂治疗晚期非小细胞肺癌近期疗效好,耐受性较好,无严重毒副反应。

    【关键词】非小细胞肺癌;多西他赛;顺铂;疗效观察

    27 examples many west his match jointly along platinum treatment later period non-cellule lung cancer curative effect observation

    DINGCun-wei

    【Abstract】Objeetive:To investigate the effect and toxicity of weekly docetaxel combined withcisplatin for advanced non-small cell lung cancer(NSCLC). Methods :Docetaxel combined withcisplatin was administered to 27 cases with advanced NSCLC. The schedule was repeated every 21 days. All patients received at least 2 cycles. Results:Overall response rate was 40.74% (CR, 2 cases; PR, 9 cases; NC, 8 cases; PD, 8 cases). The main toxicities included myelosuppression ......

您现在查看是摘要页,全文长 4986 字符